Metformin attenuates cells stemness and epithelial-mesenchymal transition in colorectal cancer cells by inhibiting the Wnt3a/β-catenin pathway

42Citations
Citations of this article
39Readers
Mendeley users who have this article in their library.

Abstract

The present study aimed to examine the roles and mechanisms of metformin in the stemness and epithelial-mesenchymal transition (EMT) of colorectal cancer cells. The formation of spheroid cells, and the results of reverse transcription-quantitative polymerase chain reaction and western blot analyses showed that metformin suppressed the ability to form spheroid cells and the expression of stemness markers in HCT116 colorectal cancer cells. Additionally, metformin attenuated the EMT process, characterized by a decrease of mesenchymal marker Vimentin and an increase in the expression of an epithelial marker. Mechanistically, metformin inactivated the Wnt3a/β-catenin signaling pathway, and reactivation of Wnt3a/β-catenin signaling attenuated the inhibition of metformin on the stemness of HCT116 colorectal cancer cells and EMT. Finally, it was revealed that metformin re-sensitized HCT116 sphere cells to 5-fluorouracil resistance. These results suggest that metformin can attenuate stemness and EMT in colorectal cancer cells.

Cite

CITATION STYLE

APA

Zhang, C., & Wang, Y. (2019). Metformin attenuates cells stemness and epithelial-mesenchymal transition in colorectal cancer cells by inhibiting the Wnt3a/β-catenin pathway. Molecular Medicine Reports, 19(2), 1203–1209. https://doi.org/10.3892/mmr.2018.9765

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free